Inhaled Amikacin for Sustained Mechanical Ventilation Patients
Authors: Christina Cuoccio, Brandon Parker, Ed Lineen – 3/20/24
Approval: Lineen, Namias – 3/20/24
Purpose
- To use inhaled amikacin to reduce rates of ventilator associated pneumonia in patients on ventilators for more than 3 days.
Procedure
- Dosing: Inhaled Amikacin 20 mg/kg of ideal body weight once daily for 3 days (Dose will be rounded to the closest 250mg vial size)
Indications
- Intubated for more than 72 hours but no more than 96 hours
Exclusion
- Allergy to amikacin
- Receiving systemic aminoglycoside
- Patients receiving treatment for suspected or confirmed pneumonia
- Creatinine clearance <30 mL/min
Ehrmann S, Barbier F, Demiselle J, et al and CRICS-TRIGGERSEP F-CRIN Research Networks; Reva and CRICS-TRIGGERSEP F-CRIN Research Network. Inhaled Amikacin to Prevent Ventilator-Associated Pneumonia. N Engl J Med. 2023 Nov 30;389(22):2052-2062. doi: 10.1056/NEJMoa2310307. Epub 2023 Oct 25. PMID: 37888914.
Purpose
- To use inhaled amikacin to reduce rates of ventilator associated pneumonia in patients on ventilators for more than 3 days.
Procedure
- Dosing: Inhaled Amikacin 20 mg/kg of ideal body weight once daily for 3 days (Dose will be rounded to the closest 250mg vial size)
Indications
- Intubated for more than 72 hours but no more than 96 hours
Exclusion
- Allergy to amikacin
- Receiving systemic aminoglycoside
- Patients receiving treatment for suspected or confirmed pneumonia
- Creatinine clearance <30 mL/min
Description
Ehrmann S, Barbier F, Demiselle J, et al and CRICS-TRIGGERSEP F-CRIN Research Networks; Reva and CRICS-TRIGGERSEP F-CRIN Research Network. Inhaled Amikacin to Prevent Ventilator-Associated Pneumonia. N Engl J Med. 2023 Nov 30;389(22):2052-2062. doi: 10.1056/NEJMoa2310307. Epub 2023 Oct 25. PMID: 37888914.